Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Necrosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  Next»
    Study title: A comparison of erythromycin and cefadroxil in the prevention of flare−ups from asymptomatic teeth with pulpal necrosis and associated periapical pathosis. Morse DR, Furst ML, Lefkowitz RD, D Angelo D, Esposito JV. Oral surgery oral medicine and oral pathology, May 1990, vol. 69, no. 5, p. 619−30.
    Active substance: ERYTHROMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 26494
    Study title: Determinants and prognostic value of ischemic necrosis in early biopsies following heart transplantEsposito 2000
    Active substance: CELSIOR
    Study summary document link (including results): Esposito 2000.pdf
    View full study record
    Document reference: 48349
    Study title: Murphy, R. and Greenberg M. Osteonecrosis in Pediatric patients with Acute Lymphoblastic Leukemia. Cancer. 04/15/90 Vol. 65:1717-1721 1990 Canada
    Active substance: DEXAMETHASONE
    Study summary document link (including results):
    View full study record
    Document reference: 25692
    Study title: Phase I study of tumor necrosis factor-alpha and actinomycin D in pediatric patients with cancer: a Children's Cancer Group study.
    Active substance: DACTINOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 25414
    Study title: Gruen GS, Mears DC, Tauxe WN. Distinguishing avascular necrosis from segmental impaction of the femoral head following an acetabular fracture: preliminary report. J Orthop Trauma. 1988;2(1):5-9. Gruen GS, Mears DC, Tauxe WN. Distinguishing avascular necrosis from segmental impaction of the femoral head following an acetabular fracture: preliminary report. J Orthop Trauma. 1988;2(1):5-9.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43829
    Study title: Comparison of bone scan and radiograph sensitivity in the detection of steroid-induced ischemic necrosis of bone. Conklin JJ, Alderson PO, Zizic TM, Hungerford DS, Densereaux JY, Gober A, Wagner HN. Radiology. 1983 Apr;147(1):221-6.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 44043
    Study title: An open study to evaluate the efficacy, safety and tolerance of the topical application of Varidase to treat patients with various kinds of open wounds with problems of inflammation, excessive accumulation of clotted blood or exudates, and tissue with necrosis.Wang et al.
    Active substance: streptokinase and streptodornase
    Study summary document link (including results):
    View full study record
    Document reference: 48947
    Study title: Burt RW, Matthews TJ. Aseptic necrosis of the knee: bone scintigraphy. AJR Am J Roentgenol. 1982 Mar;138(3):571-3. No abstract available. Burt RW, Matthews TJ. Aseptic necrosis of the knee: bone scintigraphy. AJR Am J Roentgenol. 1982 Mar;138(3):571-3. No abstract available.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 44088
    Study title: Morel C, Metge F, Roman S, Scheer S, Larricart P, Monin C et al. [Acute retinal necrosis: clinical presentation, treatment, and prognosis in a series of 22 patients]. [French]. Journal Francais d Opthalmologie 2004; 27(1):7-13.Morel C, Metge F, Roman S, Scheer S, Larricart P, Monin C et al. [Acute retinal necrosis: clinical presentation, treatment, and prognosis in a series of 22 patients]. [French]. Journal Francais d Opthalmologie 2004; 27(1):7-13.
    Active substance: FOSCARNET
    Study summary document link (including results): Morel C et al 2004.pdf
    View full study record
    Document reference: 28589
    Study title: Tran TH, Stanescu D, Caspers-Velu L, Rozenberg F, Liesnard C, Gaudric A et al. Clinical characteristics of acute HSV-2 retinal necrosis. [Review] [42 refs]. American Journal of Ophthalmology 2004; 137(5):872-879.Tran TH, Stanescu D, Caspers-Velu L, Rozenberg F, Liesnard C, Gaudric A et al. Clinical characteristics of acute HSV-2 retinal necrosis. [Review] [42 refs]. American Journal of Ophthalmology 2004; 137(5):872-879.
    Active substance: FOSCARNET
    Study summary document link (including results): Tran TH et al 2004.pdf
    View full study record
    Document reference: 28591
    Study title: Spencer JD, Maisey M. A prospective scintigraphic study of avascular necrosis of bone in renal transplant patients. Clin Orthop Relat Res. 1985 Apr;(194):125-35. Spencer JD, Maisey M. A prospective scintigraphic study of avascular necrosis of bone in renal transplant patients. Clin Orthop Relat Res. 1985 Apr;(194):125-35.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43948
    Study title: Malizos KN, Soucacos PN, Vragalas V, Dailiana ZH, Schina I, Fotopoulos A. Three phase bone scanning and digital arteriograms for monitoring vascularized fibular grafts in femoral head necrosis. Int Angiol. 1995 Sep;14(3):319-26. Malizos KN, Soucacos PN, Vragalas V, Dailiana ZH, Schina I, Fotopoulos A. Three phase bone scanning and digital arteriograms for monitoring vascularized fibular grafts in femoral head necrosis. Int Angiol. 1995 Sep;14(3):319-26.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43586
    Study title: Rhoad RC, Davidson RS, Heyman S, Dormans JP, Drummond DS. Pretreatment bone scan in SCFE: a predictor of ischemia and avascular necrosis. J Pediatr Orthop. 1999 Mar-Apr;19(2):164-8. Rhoad RC, Davidson RS, Heyman S, Dormans JP, Drummond DS. Pretreatment bone scan in SCFE: a predictor of ischemia and avascular necrosis. J Pediatr Orthop. 1999 Mar-Apr;19(2):164-8.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43511
    Study title: Knop J, Delling G, Heise U, Winkler K. Parametric imaging of 99mTc methylene diphosphonate biokinetics in osteosarcoma for preoperative evaluation of chemotherapy-induced necrosis. Chir Organi Mov. 1990;75(1 Suppl):36-7. No abstract available. Knop J, Delling G, Heise U, Winkler K. Parametric imaging of 99mTc methylene diphosphonate biokinetics in osteosarcoma for preoperative evaluation of chemotherapy-induced necrosis. Chir Organi Mov. 1990;75(1 Suppl):36-7. No abstract available.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43773
    Study title: Oh SN, Jee WH, Cho SM, Kim SH, Kang HS, Ryu KN, Cho CS. Osteonecrosis in patients with systemic lupus erythematosus: MR imaging and scintigraphic evaluation. Clin Imaging. 2004 Jul-Aug;28(4):305-9. Oh SN, Jee WH, Cho SM, Kim SH, Kang HS, Ryu KN, Cho CS. Osteonecrosis in patients with systemic lupus erythematosus: MR imaging and scintigraphic evaluation. Clin Imaging. 2004 Jul-Aug;28(4):305-9.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43400
    Study title: Bone scan in diagnosis of lymphoma with extensive bone marrow necrosis--a case report. Jain D, Pattari S, Rajesh LS, Varma N, Mittal BR. Indian J Pathol Microbiol. 2004 Jul;47(3):394-6.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43381
    Study title: Stulberg BN, Levine M, Bauer TW, Belhobek GH, Pflanze W, Feiglin DH, Roth AI. Multimodality approach to osteonecrosis of the femoral head. Clin Orthop Relat Res. 1989 Mar;(240):181-93. Stulberg BN, Levine M, Bauer TW, Belhobek GH, Pflanze W, Feiglin DH, Roth AI. Multimodality approach to osteonecrosis of the femoral head. Clin Orthop Relat Res. 1989 Mar;(240):181-93.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43792
    Study title: Neuropathic osteonecrosis of the knee in childhood. Two cases of myelomeningocele. Kjaerulff H, Hejgaard N. Acta Orthop Scand. 1987 Aug;58(4):436-40.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43852
    Study title: Group B strepto-coccus induces tumor necrosis factor in neonatal piglets: Effect of the tumor necrosis factor inhibitor pentoxifylline on haemodynamics and gas exchange. Am. Rev. Respir. Dis. 143:598-604 - Gibson - 1991 - Publication in pharmacological-toxicological expert reportGroup B strepto-coccus induces tumor necrosis factor in neonatal piglets: Effect of the tumor necrosis factor inhibitor pentoxifylline on haemodynamics and gas exchange. Am. Rev. Respir. Dis. 143:598-604 - Gibson - 1991 - Publication in pharmacological-toxicological expert report
    Active substance: PENTOXYFILLINE
    Study summary document link (including results):
    View full study record
    Document reference: 45844
    Study title: Clin Neurol Neurosurg. 2007 Sep;109(7):607-12. Epub 2007 Jun 6. Cerebral necrosis after 25Gy radiotherapy in childhood followed 28 years later by 54Gy radiotherapy. Koot RW, Stalpers LJ, Aronica E, Andries Bosch D Clin Neurol Neurosurg. 2007 Sep;109(7):607-12. Epub 2007 Jun 6. Cerebral necrosis after 25Gy radiotherapy in childhood followed 28 years later by 54Gy radiotherapy. Koot RW, Stalpers LJ, Aronica E, Andries Bosch D
    Active substance: THALLIUM 201T1 CHLORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 44539
    1  2  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 05:32:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA